• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Peripheral Arterial Disease to Be Treated With New Medicated Stent in Trial at Montefiore

Posted on: Monday, 15 October 2007, 15:00 CDT

NEW YORK, Oct. 15 /PRNewswire-USNewswire/ -- The first trial to test whether medicated, drug-eluting (dispensing), stents can benefit patients who suffer from peripheral arterial disease (PAD) is taking place at Montefiore Medical Center, one of only 80 sites around the world joining in the study.

Medicated, drug-coated stents have been used with great success for the past several years in treating coronary artery disease.

PAD affects more than 10 million Americans, according to the Peripheral Arterial Disease (P.A.D.) Coalition. The disease restricts circulation in blood vessels that lead from the heart to other areas of the body, such as the legs and feet. Often undiagnosed, PAD results in pain when walking and can lead to gangrene and amputation. It also may signal an increased risk for coronary arterial disease and other related circulatory conditions.

"This is an exciting trial since it is the first evaluation of a drug- eluting stent in blood vessels outside the heart," said Evan Lipsitz, MD, chief of Vascular Surgery at Montefiore and principal investigator of the study. "Combining a stent designed to hold blood vessels open to allow blood to flow freely through the vessel, with a medication used to prevent renarrowing, may reduce the development of scar tissue, the primary cause of the stent failure, in the months following balloon angioplasty in leg arteries.

This helps eliminate the need for more invasive treatment, such as bypass surgery," Dr. Lipsitz said.

The stent is coated with paclitaxel, a drug derived from the Pacific yew tree that has been used successfully to reduce the risk of renarrowing of arteries.

The trial is designed to determine the safety and effectiveness of the Zilver(R) PTXTM drug-eluting stent in treating blockages in the femoropoliteal artery, the major artery in the thigh.

Montefiore Medical Center, The University Hospital and Academic Medical Center for the Albert Einstein College of Medicine, encompasses 125 years of innovative medical "firsts," pioneering clinical research, dedicated community service and ground-breaking social activism.

A full-service, integrated delivery system caring for patients from New York, Westchester County and beyond, Montefiore is a 1,122-bed medical center that includes three hospitals: the Henry and Lucy Moses Division, the Jack D. Weiler Hospital and The Children's Hospital at Montefiore; a large home healthcare agency; the first and largest school health program in the U.S.; a 21-site medical group practice integrated throughout the Bronx and Westchester; and a care management organization providing services to 179,000 health plan members.

The medical center is ranked by the prestigious Leapfrog Group among the top one percent of all U.S. hospitals based on its strategic investments in sophisticated and integrated healthcare technology

Montefiore's distinguished centers of excellence include cardiology and cardiac surgery, cancer care, tissue and organ transplantation, children's health, women's health, obesity, diabetes, surgery and the surgical subspecialties. Montefiore is a leader in the treatment of headaches, cough and sleep disorders, geriatrics and geriatric psychiatry, neurology and neurosurgery, bioethics, adolescent and family medicine, HIV/AIDS and social medicine, among many other specialties.

Montefiore Medical Center

CONTACT: Steven Osborne, sosborne@montefiore.org, or Mike Quane,mquane@montefiore.org, both of Montefiore Medical Center, +1-718-920-4011

Web site: http://www.montefiore.org/

Source: PRNewswire-USNewswire

More News in this Category